FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical ...

Portal Access, Inc. Announces the closing of $7 Million Series A Financing Round to Support FDA Approval and Limited Market Launch of Next-Generation Chemotherapy Port. PR Newswire. MIAMI, May 27 ...

The FDA is already doing its own research on potential uses of AI. In December 2023 the agency advertised a fellowship for a researcher to develop large language models for internal use.

PorTal. The funds will support regulatory activities and the planned 510(k) submission for approval to the U.S. Food and Drug Administration (FDA) for Flexi-Port ™ SLF-TANL ™, a novel ...